Disclosed are tyrosine-modified rAAV vectors, as well as infectious virions,compositions, and pharmaceutical formulationsthat comprise them. Also disclosed are methods of preparing and methods forusing the disclosed tyrosine-phosphorylatedcapsid protein mutant rAAV vectors in a variety of diagnostic and therapeuticapplications including in vivo and ex vivo gene therapy,and large-scale production of rAAV vectors.